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Obesity is currently considered a serious public health issue due to its strong impact on health, economy, and quality of life. It
is considered a chronic low-grade inﬂammation state and is directly involved in the genesis of metabolic disturbances, such as
insulin resistance and dyslipidemia, which are well-known risk factors for cardiovascular disease. Furthermore, there is evidence
thatgeneticvariationthatpredisposestoinﬂammationandmetabolicdisturbancescouldinteractwithenvironmentalfactors,such
as diet, modulating individual susceptibility to developing these conditions. This paper aims to review the possible interactions
between diet and single-nucleotide polymorphisms (SNPs) in genes implicated on the inﬂammatory response, lipoprotein
metabolism, and oxidative status. Therefore, the impact of genetic variants of the peroxisome proliferator-activated receptor-
(PPAR-)gamma, tumor necrosis factor-(TNF-)alpha, interleukin (IL)-1, IL-6, apolipoprotein (Apo) A1, Apo A2, Apo A5, Apo E,
glutathione peroxidases 1, 2, and 4, and selenoprotein P exposed to variations on diet composition is described.
1.Introduction
Obesity is a global epidemic[1] and its prevalenceis growing
worldwide [2]. In 2007, prevalence in North America was
26.4% for men and 24.8% for women [3]. In developing
countries like Brazil, overweight (body mass index (BMI)
between 25 and 30kg/m2) reaches approximately 50% of
adults and obesity (BMI ≥ 30kg/m2) occurs on 16.9% of
women and 12.4% of men [4]. One billion people in the
world overweight and 300 million are considered obese.
Estimatesfor2030arethat2billionpeoplewillbeoverweight
and 1.12 billion obese around the world [5]. This scenario
m a yr e d u c el i f ee x p e c t a n c yf o rt h i sc e n t u r y[ 6], since obesity
is a major condition triggering several diseases. Particularly
accumulation of visceral fat elevates the risk of type 2
diabetes (T2DM), dyslipidemia, and hypertension, which
contribute for cardiovascular diseases, reduction in quality
of life, increase in costs of medical care, and for premature
mortality [3, 7].
Excessive energy intake combined to low-energy expen-
diture induces lipid accumulation in adipose tissue but also
in liver, muscle, and other internal organs, predisposing to
the development of insulin resistance (IR) and metabolic
disturbances [8]. In parallel to impairment of insulin action
in tissues and organs, also insulin secretion is aﬀected by
diet. It is known that high saturated fatty acids (SFAs) intake
provokes a deleterious lipid proﬁle and that the elevated
plasma-free fatty acid concentration induces apoptosis of β
cells, contributing to dysfunctional insulin secretion [9, 10].
This conditionofhigh cardiometabolic risk has been incrim-
inated in the mortality of people living in developed and in
developing countries [11–13]. Statistics indicates precocity
of cardiovascular disease, already reaching 4% of Americans
adolescents [14] being more prevalent among girls.2 Journal of Obesity
The cluster of cardiovascular risk factors led to the
description of the metabolic syndrome (MS), in which IR
represents a link between hemodynamic and metabolic dis-
turbances[15].Visceralfat accumulation,commonlypresent
in MS, contributes to a proinﬂammatory and pro-oxidant
state and to deterioration of glucose and lipid metabolism.
High amounts of free fatty acids and several adipocytokines
released from visceral adipose tissue to portal and systemic
circulation are implicated in the genesis of IR [7, 16, 17].
Tumor necrosis factor alpha (TNF-α) is a proinﬂammatory
adipocytokine whose production is increased in obese
humans and its neutralization resulted in amelioration of
IR [18, 19]. In vitro studies, in both rodents and humans,
showed that TNF-α stimulates adipocyte lipolysis [19, 20]
through downregulation of the expression of the perilipin,
a lipid droplet-associated protein which is thought to mod-
ulate the access of hormone-sensitive lipase to the surface of
the fat droplet [20]. Several evidences indicated that obesity
may generate IR via inﬂammation [21, 22]. The relationship
between obesity and subclinical inﬂammation was ﬁrstly
described by Hotamisligil in 2003 [8], who demonstrated a
positivecorrelationbetweenadiposemassandtheexpression
of the gene coding for TNF-α. Further, the link between
obesity and inﬂammation was reinforced by the ﬁndings of
increased concentrations of other inﬂammatory biomarkers
in obese individuals, like interleukin 6 (IL-6) and interleukin
8( I L - 8 )[ 21, 23] and acute phase proteins such as C reactive
protein (CRP) [6].
In addition, augmented release of TNF-α,n o n e s t e r i ﬁ e d
fatty acids and angiotensinogen, found in visceral obesity,
increases oxidative stress, which furthers contribute to IR
[24]. In this context, it has been reported that angiotensin-
ogen-II-induced reactive oxygen species (ROS) upregulation
aﬀects several parts of the intracellular insulin signalling
pathways [25]. In vitro, ROS impairs insulin receptor sub-
strate-1 (IRS-1) phosphorylation and IRS-1-induced phos-
phatidylinositol 3-kinase (PI3-kinase) activation in cultured
adipocytes, leading to the impaired translocation of glucose
transporter 4 (GLUT-4) into the membrane, resulting in IR
[26].
Modern lifestyle—characterized by high food intake
and low physical activity—has been considered the main
determinant of increased adiposity in mankind. Not only
the amount of calories contributes to the deleterious eﬀects
of obesity, since certain dietary patterns are related to
cardiovascular risk or protection. Morbidity and mortality
of Mediterranean populations are shown to be lower than
those observed in population exposed to the typical Western
diet, rich in SFA [27]. Animal studies have helped to
understand the role of dietary fat in disturbances of lipid
and glucose metabolism [28, 29]. SFA have shown to
stimulate intracellular pathways, which result in proinﬂam-
matory gene expression and/or IR [9, 10, 30, 31]. The
underlying mechanisms for deterioration of glucose and
lipid metabolism include (a) accumulation of diacylglycerol
and ceramide; (b) activation of nuclear factor-kB (NFkB),
protein kinase C, and mitogen-activated protein kinases,
and subsequent induction of inﬂammatory genes in white
adipose tissue, immune cells, and myotubes; (c) decreased
peroxisome proliferator-activated receptorgamma (PPAR-γ)
coactivator-1 a/b activation and adiponectin production,
which decreases the oxidation of glucose and fatty acids; (d)
recruitment of immune cells like macrophages, neutrophils,
and bone-marrow-derived dendritic cells to white adipose
tissue and muscle [32, 33].
Reducing consumption of foods rich in SFA and increas-
ing consumption of whole grains, fruits, vegetables, lean
meats and poultry, ﬁsh, low-fat dairy products, and oils
containing oleic acid are expected to reduce the incidence
of metabolic diseases [10, 33]. In fact, this dietary pattern,
which has similarities with the Mediterranean diet, has been
associated with better metabolic and inﬂammatory proﬁles
in some clinical trials [34].
The expression of genes is highly dependent on, and
regulated by, nutrients and dietary bioactive compounds
found in food. A variety of dietary components can alter
gene expression, and thus signiﬁcantly inﬂuence health. At
the same time, the genetic makeup of an individual may
coordinate its response to diet [35]. Investigations of gene-
environment interactions have identiﬁed genetic polymor-
phisms associated with individual susceptibility to obesity,
inﬂammation, dyslipidemia, and oxidative stress. In this
context, unbalanced diets may shift the balance between
healthy and diseased conditions, increasing the risk of these
metabolic and immune disturbances, particularly in genetic-
predisposed subjects (Figure 1).
The assessment of the interactions between nutrients,
dietary bioactive compounds, and genotypes may pave the
way for more targeted prevention strategies, and thereby
a better success in the prevention and treatment [36]. In
this context, there is increasing evidence that supports a
role for genotype-nutrient interactions in obesity and its
associated disorders [37, 38]. The present study aimed to
review the relation betweendiet and SNPsthat impact onin-
ﬂammation (PPAR-γ, Tumor Necrosis Factor alpha (TNF-
α), interleukin (IL)-1, IL-6), oxidative status (glutathione
peroxidases (GPX) 1, 2 and 4, and selenoprotein P) and
lipoprotein metabolism (apolipoprotein (Apo) A1, Apo A2,
Apo A5, Apo E).
2.PeroxisomeProliferator:Activated
ReceptorGamma
The PPARγ is a nuclear hormone receptor that serves as a
master regulator of adipocytes-speciﬁc genes contributing
to adipocytes diﬀerentiation, susceptibility to obesity, and
insulin sensitivity. Furthermore, this induces the expression
of genes that promote entrance of lipids in the cells,
synthesis triglycerides, fatty acid oxidation, and extracellular
metabolism of lipids (reverse cholesterol transport through
regulation cholesterol-eﬄux from macrophages) [39–42].
Several SNPs variants related to PPARγ gene have been
identiﬁed, like 161C/T, 1431C/T, and 162L/V, but the most
prevalent is the Pro12Ala (substitution of proline to alanine
at codon 12 of this gene, rs1801282), which is associated
w i t hT 2 D M ,o b e s i t y ,a n do t h e rc l i n i c a ld i s o r d e r s[ 43–
47]. However, the prevalence of this polymorphism variesJournal of Obesity 3
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Figure 1: The association of gene variants with diﬀerential responses to diet and its impact on the shift between homeostasis and
metabolic/immune disturbances.
according to the ethnic background of the population [43–
46, 48–54].
The relationship of SNP in the PPARγ gene and obesity
or MS is controversial. A recent research showed that
the Pro12Ala SNP was associated with obesity in Iranian
individuals, and the presence of the Ala allele predicted a
higher BMI [55]. In European descent Brazilian men [56],
andinW hitemenfr omItaly[57],theAlaalleleinteractswith
gender and contributes to the susceptibility to obesity. Also
in children of Greek origin, adiposity through measures of
skinfold triceps and subscapular was shown to be inﬂuenced
by Pro12Ala in a gender speciﬁc manner [58].
Nevertheless, a study with childhood and adult obesity
in the French Caucasian population showed that the SNP
Pro12Ala was not associated with obesity, but is conﬁrmed
a contribution in the genetic risk for T2DM especially
in obese subjects, in which this allele worsens IR and
increases fasting insulin levels [59]. Another study among
native Javaneses did not show an association between the
Pro12AlapolymorphismandT2DM;aweakassociation with
obesity was found [38]. In Poland obese individuals with
10-year history of T2DM, there was no association between
Pro12Ala SNP and body mass changes observed during the
disease course, neither diﬀerences in IR and incidence and
progression of T2DM complications [60].
In another study, fasting and postprandial triglycerides
and insulin levels as well as homeostasis model assessment
of insulin resistance (HOMA-IR) were signiﬁcantly lower in
the Ala12Ala group than in the Pro12Pro group after the
mixed meal [61]. Others conﬁrmed an association between
theAlaallele and reducedincidenceofobesityin prepubertal
childrenandfoundstrong associations betweenthisSNPand
percentage body fat [62]. Pro12Ala SNP does not seem to
be associated with BMI in postmenopausal Polish women,
although the Ala allele seems to predispose to a less favorable
lipid proﬁle in this population [63]. In Sweden, an inter-
vention study included lifestyle modiﬁcations metformin or
placebo. Metformin and lifestyle groups, Ala12 carriers had
greater weight loss [64].
In addition to the association of Ala allele with reduced
risk of T2DM [65], its presence resulted in fat oxidation
increase and higher satiety suggesting beneﬁts in food
intake control [66]. Concordantly, a study conducted in
Spanish obese woman showed that Pro12Ala SNP resulted
in increased fat oxidation [67].
Nutrients and bioactive compounds of food are able
to interfere with the genome by highly complex forms.
Studies have shown that eﬀect of Pro12Ala may be mediated
by the dietary fat [61], particularly by the proportion
of dietary polyunsaturated fatty acid (PUFA) and SFA. A
population-based cohort study, including 592 nondiabetic
Caucasian, showed that fasting insulin concentration was
negativelyassociated withthedietaryPUFA-to-SFAratioand
a strong interaction was evident between this ratio and the
Pro12Ala polymorphism for both, BMI and fasting insulin,
suggesting that when the dietary ratio is low, the BMI in
Ala carriers is greater than that in Pro homozygotes, but
when the dietary ratio is high, the opposite is seen [68]. In
a Spanish population similar results were found; the intake
of monounsaturated fatty acid (MUFA) mainly oleic acid,
contributed to the variance of the HOMA-IR.These ﬁndings
suggest the existence of an interaction between Pro12Ala
and dietary MUFA, such that obese people with the Ala-12
allele havehigher HOMA-IRvalues, especially if theirMUFA
intake is low [69]. Studying the P12Ala with Glu27Glu
polymorphism of beta 2-adrenergic receptor, Rosado et al.,4 Journal of Obesity
[67], showed that individuals carrying both polymorphisms
Pro12Ala and Gln27Glu alleles had high PUFA intake and
greater body weight loss. Similar results were shown in
study with children. Pro12Ala may be associated with higher
insulin sensitivity and higher long-chain PUFAs, particularly
n-3, levelsin plasma phospholipids of 140 Italian normolipi-
demic obese children [70]. This gene-nutrient interaction
emphasizes the diﬃculty of examining the eﬀect of common
polymorphisms in the absence of data about environment
exposures.
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
3.TumorNecrosis FactorAlpha
TNF-α is a pleiotropic cytokine with a central role in
inﬂammation. Obesity leads to an increased production of
TNF-α, which is a crucial mediator of IR states and other
related comorbidities [85–87].
TNF-α production in whole blood cell culture of healthy
individuals shows a great, thoughstable, variation, making it
possible to identify high and low producerphenotypes in the
population [88, 89]. This fact points to a substantial genetic
contribution to TNF-α regulation [90, 91]. The TNF gene is
located on human chromosome 6p21.3in the class III region
of the major histocompatibility complex [92].
Eight SNPs were described within the TNF promoter,
at positions −1031T/C, −863C/A, −857C/T, −575G/A,
−376G/A, −308G/A, −244G/A, and −238G/A [91, 92].
Regulating the transcription of TNF gene could potentially
bluntthedeleteriouseﬀectsofdysregulated TNF-αsynthesis,
as seen in obesity-induced inﬂammation. As such, genetic
variations in TNF gene regulatory region may aﬀect TNF-α
transcriptionandexpression,inﬂuencingthedevelopmentof
conditionsassociated with excessiveTNF-αproduction,such
as rheumatoid arthritis, inﬂammatory bowel disease and IR
[93].
Wilson et al. [94] identiﬁed the polymorphism located
at position −308 in the TNF promoter (rs1800629), which
deﬁned the TNF1 (−308G) and TNF2 (−308A) alleles. The
presence of TNF2 allele seems to be associated with a greater
risk of diseases, mainly infectious and autoimmune diseases
[95]. However, results concerning the possible functional
role of −308 TNF polymorphism are conﬂicting [96]. Gene
reporter assays have been employed to investigate whether
the TNF 2 allele could inﬂuence TNF-α gene transcription.
Some studies show signiﬁcant diﬀerences in transcriptional
activity between TNF1 and TNF2 alleles [97–99], while
others could not conﬁrm these ﬁndings [99, 100]. Some
of the variables that might explain the mixed results of
these experiments are diﬀerences in cell type used for
transfection, cell origin (human or nonhuman), type of
stimulus (lipopolysaccharide, phorbol myristate acetate, and
TNF-α), length of the promoter sequence used and the
presence or absence of the 3 untranslated regions of the
mRNA (3 UTR).
Nonobese healthy individuals carrying TNF2 allele
showed an increase in circulating inﬂammatory biomarkers
s u c ha sC R Pi ns o m e[ 101, 102] but not all studies [103]. It
is noteworthy that this relationship was conditioned by age,
gender, and ethnicity [101, 102]. A meta-analysis aiming to
investigate whether −308G/A TNF-α gene variant was asso-
ciated with MS phenotype found that carriers of the TNF2
allele had higher systolic blood pressure and fasting insulin,
which appeared to be dependent of age group and ethnic
b a c k g r o u n d ,h o w e v e r ,t h e r ew a sn os i g n i ﬁ c a n ta s s o c i a t i o n
of TNF-α genotypes with plasma fasting glucose and leptin,
T2DM and hypertension [104]. Concerning cardiovascular
events, another meta-analysis failed to ﬁnd an association
of −308G/A polymorphism with ischemic heart disease and
ischemic stroke, except for Asians in which carrying −308
variant seemed to be protective [105].
Some studies reported that the presence of −308G/A
TNF-α polymorphism may aﬀect the individuals’ response
to supplementation of dietary components such as ﬁsh oil
and vitamin E [71, 72]. In this context, Grimble et al. [71]
reported that supplementing ﬁsh oil (6g/day for 12 weeks)
in healthy men decreased TNF-α production by lipopoly-
saccharides-stimulated peripheral blood mononuclear cells
only in individuals with high TNF-α producer phenotype,
irrespective of genotype. Nevertheless, the suppressive eﬀect
ofﬁshoilsupplementationonTNF-αproductionwasgreater
among individuals in the highest tertile of presupplementa-
tion with the TNF1/TNF2 genotype compared to the wild-
type individuals.
In a randomized, double-blind, placebo-controlled trial,
elderly men and women received vitamin E supplementation
(182mg α-tocopherol) for one year. The ex vivo production
of interleukin 1 β (IL-β), IL-6, and TNF-α was determined
in whole blood samples incubated with lipopolysaccharide
(LPS) (either 1.0 or 0.01mg/L) for 24h. Althoughthere were
nooveralldiﬀerenceswithrespect totreatment groupforany
ofthe cytokines,when genotypewastakeninto account,par-
ticipants with the A/A and A/G genotype at TNF −308G/A,
treated with vitamin E, had lower TNF-α production than
those with the A allele treated with placebo [72].
There is also some evidence that carrying TNF2 allele
may inﬂuence diet response in obese individuals. Obese
nondiabetic individuals were randomly allocated to 2 types
ofenergy-restricteddietsfor2months:adietlowerinfat(LF:
1500kcal/day, 52% carbohydrates, 20% proteins, and 27%
fats) and a diet lower in carbohydrates (LC: 1507kcal/day,
38% carbohydrates, 26% proteins, and 36% fats). The results
of this study indicated that obese subjects carrying the TNF2
allele responded diﬀerently to the diets since, contrary to
the wild genotype individuals, no improvement in plasma
glucose, insulin, triglyceride, total cholesterol, low density
lipoprotein(LDL),and bloodpressure was observed.Despite
the fact that both genotype groups have lost fat mass
following theinterventions, it is important toemphasize that
such decrease in fat mass was slightly smaller in −308G/A
individuals (LF diet: 5.0% versus 6.5%; LC diet: 4.9% versus
7.3%) [73].
Another study [74] reported signiﬁcant interactions
between dietary fat intake and TNFA −308G/A polymor-
phism aﬀecting obesity risk in a sub-Saharan women
population. When the dietary fat intake was 30 (% energy),Journal of Obesity 5
T
a
b
l
e
1
:
S
u
m
m
a
r
y
o
f
s
t
u
d
i
e
s
e
v
a
l
u
a
t
i
n
g
i
n
t
e
r
a
c
t
i
o
n
b
e
t
w
e
e
n
d
i
e
t
a
n
d
v
a
r
i
a
n
t
s
o
f
g
e
n
e
s
i
n
v
o
l
v
e
d
i
n
i
n
ﬂ
a
m
m
a
t
i
o
n
a
n
d
o
x
i
d
a
n
t
s
t
a
t
u
s
.
G
e
n
e
V
a
r
i
a
n
t
P
o
p
u
l
a
t
i
o
n
[
r
e
f
e
r
e
n
c
e
]
F
r
e
q
u
e
n
c
y
D
e
s
i
g
n
M
a
i
n
ﬁ
n
d
i
n
g
s
7
0
8
m
e
n
f
r
o
m
G
e
r
m
a
n
y
[
6
1
]
P
r
o
:
8
5
%
A
l
a
:
1
5
%
M
e
t
a
b
o
l
i
c
t
o
l
e
r
a
n
c
e
t
e
s
t
:
o
r
a
l
g
l
u
c
o
s
e
t
o
l
e
r
a
n
c
e
t
e
s
t
a
n
d
o
r
a
l
m
e
t
a
b
o
l
i
c
t
o
l
e
r
a
n
c
e
t
e
s
t
(
m
i
x
e
d
m
e
a
l
c
o
n
t
a
i
n
i
n
g
5
1
,
6
k
J
%
f
a
t
,
2
9
,
6
k
J
%
c
a
r
b
o
h
y
d
r
a
t
e
s
,
1
1
,
9
k
J
%
p
r
o
t
e
i
n
,
w
i
t
h
a
t
o
t
a
l
o
f
4
4
0
6
k
J
.
F
a
s
t
i
n
g
a
n
d
p
o
s
t
p
r
a
n
d
i
a
l
s
e
r
u
m
T
G
,
i
n
s
u
l
i
n
l
e
v
e
l
s
a
n
d
H
O
M
A
-
I
R
w
e
r
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
l
o
w
e
r
i
n
t
h
e
A
l
a
1
2
A
l
a
g
r
o
u
p
t
h
a
n
i
n
P
r
o
1
2
P
r
o
g
r
o
u
p
a
f
t
e
r
t
h
e
m
e
t
a
b
o
l
i
c
t
o
l
e
r
a
n
c
e
t
e
s
t
.
P
P
A
R
-
g
a
m
m
a
P
r
o
1
2
A
l
a
(
r
s
1
8
0
1
2
8
2
)
T
o
t
a
l
o
f
3
,
3
5
6
i
n
d
i
v
i
d
u
a
l
s
f
r
o
m
D
i
a
b
e
t
e
s
P
r
e
v
e
n
t
i
o
n
P
r
o
g
r
a
m
,
U
S
A
[
6
4
]
A
l
a
f
r
e
q
u
e
n
c
i
e
s
:
E
u
r
o
p
e
a
n
A
m
e
r
i
c
a
n
s
:
1
1
,
7
%
A
f
r
i
c
a
n
A
m
e
r
i
c
a
n
s
:
4
%
H
i
s
p
a
n
i
c
s
:
9
%
A
m
e
r
i
c
a
n
I
n
d
i
a
n
s
:
1
9
,
6
%
A
s
i
a
n
:
8
,
6
%
R
a
n
d
o
m
i
z
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
t
r
e
a
t
m
e
n
t
w
i
t
h
m
e
t
f
o
r
m
i
n
,
t
r
o
g
l
i
t
a
z
o
n
e
,
o
r
l
i
f
e
s
t
y
l
e
m
o
d
i
ﬁ
c
a
t
i
o
n
v
e
r
s
u
s
p
l
a
c
e
b
o
f
o
r
T
2
D
M
p
r
e
v
e
n
t
i
o
n
i
n
h
i
g
h
-
r
i
s
k
i
n
d
i
v
i
d
u
a
l
s
.
I
n
P
r
o
h
o
m
o
z
y
g
o
u
s
,
V
A
T
w
a
s
r
e
d
u
c
e
d
t
o
a
s
i
m
i
l
a
r
d
e
g
r
e
e
i
r
r
e
s
p
e
c
t
i
v
e
o
f
t
h
e
l
e
v
e
l
o
f
p
o
l
y
u
n
s
a
t
u
r
a
t
e
d
/
s
a
t
u
r
a
t
e
d
f
a
t
t
y
a
c
i
d
r
a
t
i
o
(
P
:
S
r
a
t
i
o
)
i
n
t
h
e
d
i
e
t
.
A
l
a
1
2
a
l
l
e
l
e
c
a
r
r
i
e
r
s
w
h
e
r
e
c
o
n
s
u
m
i
n
g
l
o
w
P
:
S
r
a
t
i
o
d
i
e
t
s
t
e
n
d
e
d
t
o
g
a
i
n
V
A
T
m
a
s
s
,
w
h
e
r
e
a
s
t
h
o
s
e
w
h
o
c
o
n
s
u
m
e
d
h
i
g
h
P
:
S
r
a
t
i
o
d
i
e
t
s
t
e
n
d
e
d
t
o
l
o
s
e
V
A
T
.
I
n
m
e
t
f
o
r
m
i
n
a
n
d
l
i
f
e
s
t
y
l
e
g
r
o
u
p
s
,
A
l
a
1
2
c
a
r
r
i
e
r
s
h
a
d
g
r
e
a
t
e
r
w
e
i
g
h
t
l
o
s
s
.
5
9
2
n
o
n
d
i
a
b
e
t
i
c
C
a
u
c
a
s
i
a
n
f
r
o
m
U
K
[
6
8
]
P
r
o
/
P
r
o
:
7
9
,
1
%
A
l
a
/
A
l
a
:
2
%
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
W
h
e
n
t
h
e
a
m
o
u
n
t
o
f
S
F
A
i
n
t
h
e
d
i
e
t
i
s
g
r
e
a
t
e
r
t
h
a
n
t
h
e
a
m
o
u
n
t
o
f
P
U
F
A
,
t
h
e
B
M
I
o
f
A
l
a
c
a
r
r
i
e
r
s
i
s
h
i
g
h
.
W
h
e
n
t
h
e
a
m
o
u
n
t
o
f
P
U
F
A
i
s
g
r
e
a
t
e
r
t
h
a
n
t
h
e
S
F
A
,
t
h
e
o
p
p
o
s
i
t
e
e
ﬀ
e
c
t
i
s
o
b
s
e
r
v
e
d
.
S
t
r
o
n
g
i
n
t
e
r
a
c
t
i
o
n
w
a
s
e
v
i
d
e
n
t
b
e
t
w
e
e
n
P
U
F
A
/
S
F
A
r
a
t
i
o
i
n
t
h
e
d
i
e
t
a
n
d
P
r
o
1
2
A
l
a
f
o
r
b
o
t
h
B
M
I
a
n
d
s
e
r
u
m
f
a
s
t
i
n
g
i
n
s
u
l
i
n
c
o
n
c
e
n
t
r
a
t
i
o
n
.
5
3
8
s
u
b
j
e
c
t
s
f
r
o
m
s
o
u
t
h
e
r
n
S
p
a
i
n
[
6
9
]
P
r
o
1
2
P
r
o
:
8
5
,
8
P
r
o
1
2
A
l
a
:
1
3
,
4
%
A
l
a
1
2
A
l
a
:
0
,
8
%
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
S
u
b
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c
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b
e
s
e
p
e
o
p
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p
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c
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=
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i
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c
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ﬁ
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ﬀ
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p
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p
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p
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p
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d
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m
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c
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p
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c
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p
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p
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.
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i
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p
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c
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c
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c
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c
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c
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.
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c
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c
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c
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c
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c
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i
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p
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i
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p
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n
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i
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i
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c
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d
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w
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c
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l
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the odds of being obese with the TNF-α GA+AA genotype
was only 12% of that with GG, and at 35 (% energy) it was
33%. However, increasing intake of dietary fat (% energy)
was associated with a signiﬁcantly faster rate of increase in
obesity risk in women with the TNF-α GA+AA genotype
compared with those with the GG genotype (P = .036).
For individuals with the GG genotype, the obesity OR was
1.12 and 1.26 for total dietary fat intakes of 35 and 40 (%E),
respectively, compared with 30 (% energy). On the other
hand, for individuals with the GA+AA genotype, the obesity
OR was 3.02 and 9.12 for total dietary fat intakes of 35
and 40 (%E), respectively, compared with 30%E, indicating
that individuals carrying A allele were signiﬁcantly more
responsive to an increase in dietary fat intake in their risk
of being obese compared with normal weight.
Inﬂammatory status is characterized by the production
ofawiderangeofmediatorsthatwork inacomplexnetwork.
Thus, studying only one gene is not suﬃcient to understand
the complex nutrient-gene interactions that take place in
obesity-inducedinﬂammation. Inthiscontext,acase-control
study evaluated the additive eﬀect of polymorphisms in
TNF-α,l y m p h o t o x i n - α (LTA), and IL-6 genes in MS. The
risk genotype, characterized by the combination of the LTA
rs915654 A allele, the TNF GG, and the IL-6 rs1800797
GG genotype were associated with an increased risk of MS
when compared to noncarriers (OR 2.10, 95% P<. 005).
Interestingly, such association was aﬀected by plasma fatty
acid proﬁle. Among carriers of the 3 risk genotypes with the
lowest 50th percentile of PUFA/SFA, MS risk was increased
more than 4-fold compared with noncarriers (OR 4.40, P<
.005).Similarly, a low PUFA/SFAexacerbated the risk offast-
ing hyperglycemia, high systolic blood pressure, abdominal
obesity, and high plasma complement component 3 (C3)
levels in these individuals. Also, MS risk was more than 5-
fold higher in the risk genotype carriers with the highest SFA
levels compared with noncarriers (OR 5.20, P<. 005) [106].
Another TNF-α genetic variant that has received atten-
tion in the context of MS and chronic diseases is the TNF
238G/A polymorphism (rs 361525), which is located within
a TNF gene repressor site whose eﬀect on transcription
activity still remains unknown [92]. The association between
TNF 238G/A polymorphism and T2DM in case-control
studies has generated conﬂicting results. A recent meta-
analysis indicated that the TNF 238G/A polymorphism did
not increase the risk of T2DM.
It has been suggested that there is linkage disequilibrium
between the −238, −308, and −376 (rs1800750) polymor-
phisms. The −376A allele preferentially segregates with the
−308G and the −238A alleles in most Africans and in
Europeans [92, 122]. This fact has allowed the study of
haplotypes, groups of SNPs that are inherited together in
blocks. Using haplotype approaches to identify functional
loci is interesting since multiple polymorphic loci may have
combined eﬀects on expression [97] .I nt h ec a s eo fT N F - α
gene, the haplotypes −238G, −308A, and −376G are associ-
ated with higher TNF-α production, while −238A, −308G,
and −376A are associated with lower TNF-α production,
which may depend on the racial group [92]. Unfortunately,
at present, no study investigated the eﬀe c to fd i e to ri t s
components on obesity-induced inﬂammation according to
individuals’ TNF-α haplotype.
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
4.Interleukin-6
IL-6 is secreted by a wide variety of cells such as endothelial
cells, keratinocytes, osteoblasts, myocytes, adipocytes, β
pancreatic cells, monocytes, macrophages, and a number
of other tissues, including a few tumors. This cytokine is
essential in reducing the inﬂammatory process by promot-
ing the synthesis of anti-inﬂammatory cytokines and by
negatively regulating inﬂammatory targets. Therefore, this
protein has been classiﬁed as both a pro- and anti-inﬂam-
m a t o r y ;a tc e r t a i nl e v e li ta c t sa sad e f e n s em e c h a n i s m
but in chronic inﬂammation it has rather proinﬂammatory
properties [123–125]
In humans, higher circulating IL-6 levels have been
associated with obesity and visceral fat deposition [126–
128], increased risk of impaired glucose tolerance, T2DM
[126, 129–131], and high blood pressure [132, 133]. IL-
6 is a central mediator of the acute-phase response and a
primary determinant of hepatic production of CRP [134,
135].Visceraladipose tissuesecretesabouttwotothreetimes
more IL-6 than subcutaneous tissue, secreting also other
molecules that stimulate further IL-6 expression.
The associations between common variations in the IL-6
gene and obesity have been examined in many studies [136–
141]. The human gene of IL-6 is located on the short arm
of chromosome 7 (7p21). In the last years many diﬀerent
SNPs in the promoter region of this gene were reported,
like −572G/C, −373A(n)T(n), −597G/A (rs10242595), and
−174G/C (rs1800795), the latter being the most prevalent
and of greatest biological importance [142].
In a population-based cross-sectional study in Sweden,
SNP −597G/A (minor allele frequency = 29%) 3  of the IL6
gene was negatively associated with the primary outcome
total body fat mass (BFM) (eﬀect size −0.11 SD per A
allele, P = .02). When results from three cohorts were
combined (n = 8,927 Caucasians), allele A showed a
negative association with total BFM (eﬀectsize −0.05 SD per
A allele, P<. 0002). Furthermore, the allele A was associated
with lower BMI (eﬀect size −0.03, P<. 001) and smaller
regional BFM [143].
As far as the SNP −174G/C (rs1800795) is concerned,
three genotypes G/G, G/C, and C/C seem to aﬀect the IL-
6 transcription (116,119). Genotype G/C is more frequently
reported by most studies [142]. In a population-based study
including 9,960 Americans, it was shown frequencies of this
SNPof0.57inCaucasiansand0.93inAfro-Americans [144].
The presence of C allele has been related with a higher
risk of obesity, high BMI, high waist circumference (WC),
high leptin levels, and high BFM [145, 146]. Both studies
with a Swedish and Canadian population reported associa-
tion of the C allele with obesity indices [136]. Carriers of
the CC genotype had lower energy expenditure and insulin
sensitivity, hence implying a causative role in IR and obesityJournal of Obesity 11
[77, 147]. The C allele was associated with higher BMI in
T2DM individuals, but not amongst healthy subjects [134].
Studies relate G allele with an increase production of IL-6
[142].The GGgenotypeinSpanishCaucasianwasassociated
with T2DM [148]. In a Spanish population, the G allele
was associated with hyperglycaemia with a reduction in
insulin sensitivity [77] and with lipid proﬁle disturbance
[149]. Contradicting others ﬁndings, a recent study with 228
patients with T2DM and 300 healthy controls in Tunisia, the
SNP −174G/C was not associated with T2DM or risk for
overweight (P = .86). Bonferroni correction showed that
the association of the SNP with T2DM susceptibility was
restricted to overweight individuals and may be likely to be a
randomresult[150].Ontheotherhand,itwasdescribedthat
the individuals with GG genotype lost weight signiﬁcantly
after aerobic exercises training. This eﬀe c tw a sn o to b s e r v e d
inheterozygousneitherthehomozygousCCindividualswho
did not reduced the fat mass and insulin levels after the
physical activity [146]. In addition we observed a higher
incidence of G allele in subjects with normal weight (BMI <
25kg/m2)[ 136].
Whereas severalstudiesindicatethat Calleleisassociated
with higher plasma levels of IL-6, particularly in inﬂamma-
tory situations [151, 152], in study including obese men, this
SNPwas associated with variation of plasma CRPconcentra-
tion after weight loss [153]. A study with 504 Spanish ado-
lescents shows no diﬀerences between genotypes observed
in anthropometric values, body composition measurements,
andplasmamarkersconcentration.Physicalactivityleveldif-
fers between genotypes with individuals carrying the C allele
polymorphism being signiﬁcantly moreactive thanGG ones.
The association between body fat mass and plasma glucose
was inﬂuenced by this SNP. Those carrying the C allele of the
mutationseemtohavehighervaluesoflipoproteinsandCRP
as their percentage of BFM increases [154]. Nevertheless,
the C allele was more frequently observed (P = .032)
in individuals with successful weight maintenance (<10%
weight regain). Moreover, the presence ofthe Alaallele of the
PPAR-γ togetherwith the C allele ofthe IL-6 strengthens this
protection(OR0.19;P = .043),suggesting a synergetic eﬀect
of both variants on weight maintenance after a diet to lose
weight [78].
Fern´ andez–Real et al. [77] ,s t u d y i n gt h es a m eS N P ,
observed in healthy individuals that those with the G alelle
presented concentration two times bigger of triglycerides
than the ones with C allele, suggesting that the associated
to a bigger secretion of IL-6 can predispose disturbs of
lipid metabolism. Berthier et al. reported that GG allele
was more common among lean men, and those with lower
plasma concentrations of insulin and glucose following an
oral glucose tolerance test [155].
Recent ﬁndings show that individuals with certain
polymorphism can respond diﬀerently to diet than those
without polymorphism. The association between variation
infatoxidationratesamongobesesubjectsandgenotypewas
studied for 42 common SNPs. Subjects with GC phenotype
ofSNP −174 had higher ability to increase fat oxidation after
a high fat load (P = .01) [75]. In a Spanish study, after a 3-
year intervention with a Mediterranean-style diet conducted
in a high cardiovascular risk population, CC individuals
with the −174G/C polymorphism were predicted to have
the greatest reduction in body weight. At baseline these
individuals had the highest body weight and BMI [76].
Therefore, the body of evidence suggests that variation
in IL-6 gene is associated with metabolic and cytokine mod-
ulation, and subsequently may play an important role in
impairedglucoseandlipidhomeostasis,cardiometabolicrisk
and seems to inﬂuence how the individual responds to fat
intake. Results are still controversial and further studies on
this issue are needed.
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
5.Interleukin-1β
Together with TNF-αand IL-6, IL-1β also playsa central role
in theregulationof theimmuneresponses andinﬂammatory
process. IL-1β regulates the production of a variety of
inﬂammatory mediators, such as IL-6, intercellular adhesion
molecule (ICAM)-1, and E-selectin [156, 157], and it has
beenassociated with metabolicdisturbancespresent inobese
subjects such as dyslipidemia and IR [158, 159].
The IL-1 family ofgenescomprises9 genes,includingthe
IL-1A, IL-1B, and IL-1 receptor antagonist gene (IL-1RN),
which are all locatedon thelongarmofhuman chromosome
2. Of the gene products, IL-1α and IL-1β are agonists,
whereas IL-1 receptor antagonist (IL-1Ra) is a competitive
antagonist of the IL-1 receptor and is, therefore, a negative
regulator of inﬂammation [160, 161].
Current data indicate that some SNPs in IL-1B gene
are associated with increased levels of IL-1β and other
inﬂammatory markers such as CRP,suggesting a relationship
between IL-1 gene variants and systemic inﬂammation.
In patients with established coronary heart disease, IL-1B
(+3954)T allele correlated with increased CRP levels, even
after adjusting for smoking status, BMI, total cholesterol,
and the presence of DM [162]. In a larger study performed
in 454 subjects undergoing coronary angiography, individ-
uals homozygous for IL-1B (+3954)T allele had 2- to 3-
fold higher CRP levels than wild-type individuals, which
remained signiﬁcant afteradjusting forgender,smoking,and
age [163]. Another study reported that the presence of −511
T(rs1143627)decreasedIL-1βproductioninLPS-stimulated
mononuclear cells and that homozygous subjects for T
genotype showed a decreased risk of myocardial infarction
(OR 0.36) and stroke (OR 0.32) [164].
Given the role of IL-1RA in modulating the biological
activity of IL-1, polymorphic variants in IL-1RN gene may
aﬀect IL-1RA production, inﬂuencing the inﬂammatory
response. In fact, there is evidence that minor alleles
of IL1RN 1018 (rs4251961) and 13888 (rs2232354) are
associated with increased levelsof inﬂammatory biomarkers,
such as IL-1β,C R P ,ﬁ b r i n o g e n ,I L - 6 ,i n t e r f e r o n - γ,a n d
α-2 macroglobulin (a hepatic acute phase protein). Also,
these polymorphisms are associated with lower IL-1RA
concentration and ex vivo cellular production in response to
an inﬂammatory stimulus [79, 165].12 Journal of Obesity
In cross-sectional study with a predominantly Caucasian
population, adjusted odds ratio for MS was signiﬁcantly
greater in subjects carrying 6054G allele, while it was
signiﬁcantly lower in individuals carrying −511G and
−1473G IL-1β allele. This study also provided informa-
tion on the interaction between genotype and membrane
fatty acid content, a surrogate of habitual dietary fatty
acid intake, in determining MS risk. Among individuals
in the lowest 50th percentile of total PUFA or total
n-3 PUFA—eicosapentaenoic acid+docosahexaenoic acid
(EPA+DHA)—carriers of 6054G had a higher prevalence
of MS when compared to wild-type individuals; such
association was not found in the highest 50th percentile of
total PUFA or total EPA+DHA membrane content, which
suggests that EPA+DHA may be helpful in preventing MS
in 6054G genetic predisposed individuals. The authors also
examined a haplotype consisting of 5 SNPs: 6054G/A,
3966C/T, 231T/C, 2511G/A, and 21473G/C and found that
individuals with haplotype 11222 had higher prevalence of
MSthanhaplotype21111.AmongthosewithlowDHA+EPA
membrane content, there was signiﬁcant haplotype asso-
ciation with MS, being OR of MS for haplotype 11222
signiﬁcantlyhigherthanforhaplotype21111.However,there
was no signiﬁcant association among individuals with high
membrane DHA+EPA content [166].
Another study found an association between the preva-
lence of hypertension and the presence of −31C allele, which
could be modiﬁed by plasma β-carotene levels. Male CC
carriers with high serum β-carotene levels had a signiﬁcantly
lower OR (OR 0.25, P<. 05) for hypertension relative to
those with low serum β-carotene levels. The association of
the IL-1B −31C/T polymorphism with hypertension was
weak in women with high β-carotene circulating levels, but,
in those with low β-carotene levels, the TT genotype clearly
increased the prevalence of hypertension (OR 2.47, P<. 05).
The results were not adjusted to some known risk factors for
hypertension as smoking/drinking habits, menopause, and
diet [80].
A randomized placebo-controlled trial was carried out
in healthy adults to evaluate the eﬀect of 12-week sup-
plementation with a formulated botanical extract rich in
dehydroascorbate, anthocyanins, and all-trans-resveratrol
(1200mg/d of rose hips extract, 165mg/d of blackberry
powder, 330mg/d of blueberry powder, and 40mg/d of
grapevine extract) on inﬂammation in individuals with
genetic variations that predispose to overexpression of IL-
1β. Individuals were stratiﬁed by IL-1 genotype prior to
randomization. They were classiﬁed as IL-1 positive geno-
type if they had any of the following 3 genotypes: (1)
homozygous for the common allele (C) at IL1B (−511); (2)
carrying 2 copies of the less common allele (T) at IL1A
(+4845); or (3) carrying one copy of the less common
allele at IL1A (+4845) plus at least one copy of the less
common allele (T) at IL1B (+3954). IL-1 positive genotype
individuals receiving the formulation experienced a greater
reduction in IL-1B gene expression and in plasma CRP levels
[81].
Current data is clearly insuﬃcient to draw deﬁnite con-
clusions; however, it seems likely that some polymorphisms
in IL-1 gene may aﬀe c td i e tr e s p o n s ei ns o m ep r o i n ﬂ a m m a -
tory conditions.
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
6.ApolipoproteinA1
Apo A1 is the major protein component (roughly 70%)
of high-density lipoproteins (HDL), which is synthesized
primarily in the liver and small intestine, and acts in
the transport of cholesterol from the peripheral tissues to
the liver. Apo A1 plays a crucial role in the regulation
of reverse cholesterol transport [167–169]. Upon secretion
into plasma, Apo A1 is lapidated through ATP-binding
cassette transporter-(ABC-)A1 that mediated eﬄux of free
cholesterol and phospholipids, resulting in the formation of
nascent disc shaped HDL particles [170].
More than a dozen functionally signiﬁcant mutations of
the ApoA1genehave beendescribed,includinggenedisrup-
tions, nonsense mutations, frameshifts, missense mutations,
chromosomal aberrations or deletions, and inversion of
the APOA1/APOA3/APOA4 gene cluster; these are typically
associated with decreased plasma HDL concentration [171–
174].
Overexpression of the human Apo A1 gene in mice
increased plasma HDL concentration and protected the ani-
mals from the development of high-fat diet-(HFD-)induced
atherosclerosis [175]. Conversely, Apo A1 knockout mice
exhibited decreased plasma HDL concentration and devel-
oped atherosclerotic lesions [176].
Apo A1 missense mutations are a type of nonsynony-
mous mutation that causes a single nucleotide change,
resulting in a codon that codes for a amino acid, which
turns the protein without function. This kind of structural
v a r i a t i o nh a v ea l s ob e e nf o u n da n d ,a l t h o u g ht h e r ea r e
exceptions [177], most of these do not change plasma
HDL concentration. However, a well-known variant of the
Apo A1, called A-I Milano (apoA-IM), is associated with
r educedHDLandLDLlev els[178,179].This polymorphism
is a variant form of Apo A1 that contains a cysteine
replaced by arginine at amino acid 173 (R173C) [180].
Moreover, Calabresi et al. [181] showed that carriers of the
apoA-IM mutation have an increased postprandial lipemic
response. Another polymorphism called PstI (rs12721026)
is located in the 30 ﬂanking region of Apo A1 gene and
has been associated with the development of cardiovascular
disease and decreased plasma HDL concentration [182,
183].
A common G to A substitution in the promoter area
at position −76bp (−76G/A) of the Apo A1 gene has been
extensively studied and some researchers have observed that
carriers of this polymorphism presented an increase in the
promoter activity in vitro and plasma HDL concentration
[184, 185]. Also, Mar´ ın et al. [186] observed that carriers of
this mutation have a greater postprandial increase in large
triglyceride-rich lipoproteins and a smaller decline in LDL
and Apo B, after the ingestion of a dietary fat load than
carriers of the G/G genotype.Journal of Obesity 13
The minor allele of MspI polymorphism, consisting of
a G to A transition at position −75bp (rs799837), has
been associated in a number of studies with higher Apo
A1 and HDL plasma levels [187], although others were
unable to conﬁrm this relation [188]. Moreover, such pol-
ymorphism may contribute to variability in postprandial
lipid metabolism and in the lipoprotein response to dietary
changes in healthy subjects [107].
Some dietary factors have been extensively studied and
related to the mutation of Apo A1 gene. The total dietary fat
and the type of fat are the main cited interactions resulting
in serum lipids alterations. Gomez et al. [107]i n v e s t i g a t e d
whether the presence of the −76G/A SNP in the Apo A1
geneinteracts with diet to determine changesin LDL particle
size and their susceptibility to oxidative modiﬁcations. In a
second step, they examined these eﬀects by analyzing the
contribution of the combination of the Apo A1 −76G/A
and Apo A4 Thr347Ser SNP. Each of 97 healthy volunteers
consumed 3 types of diet for 4 weeks: a high-saturated fat
diet (38% fat, being 20% SFA), 12% monounsaturated fatty
acids (MUFA), and 6% polyunsaturated (PUFA) followed
by a low-fat and high-carbohydrate (CHO) diets (30% fat,
55% CHO) or a MUFA diet (38% fat, 22% MUFA). After
consuming the CHO diet, there was a signiﬁcant decrease in
LDL size with respect to high-fat diets in GG homozygotes
for the Apo A1 −76G/A SNP. However, LDL size did not
diﬀer in GA carriers among participants consuming the 3
diets. Carriers of the A allele for this polymorphism had
smaller LDL size as well as increased susceptibility to oxida-
tion after the SFA diet than the GG homozygous.
Ordovas et al. [108] examined whether dietary fat mod-
ulates the association between the −75G/A of Apo A1 poly-
morphismandplasmaHDLconcentration.Participants (755
men and 822 women) of the Framingham Oﬀspring Study
were divided into low (<4% of energy), medium (4–8% of
energy), and high (>8% of energy) PUFA intake. Women
who were carriers of the A allele submitted to high PUFA
intakeincreasedplasmaHDLconcentrationsigniﬁcantly,but
in homozygous women for the G allele an inverse relation
was found. This meant that when PUFA intake provided
<4% of energy, women who were homozygous for the G
allele had almost 14% higher plasma HDL concentration
than A allele carriers and when PUFA intake provided >8%
of energy, plasma HDL concentration in carriers of the
A allele were 13% higher than those of G/G individuals.
Thereby, a signiﬁcant interaction in terms of plasma HDL
concentration was observed between Apo A1 genotype and
PUFAintake.Nosigniﬁcant association was detectedin men.
The soy protein has been associated with improvement
on lipid levels and the mechanisms by which it acts
include several metabolic pathways regulated by diﬀerent
transcription factors. Animals who consumed a long-term
of soy protein had a decrease in insulin/glucagon ratio,
due mainly to a reduction in insulin secretion [189]a n d
an increase in glucagon concentration, that leads to an
expression reduction in the transcriptional factor sterol
regulatory element-binding protein (SREBP)-1 [190], which
is involved in fatty acid synthesis and triglyceride (TG)
esteriﬁcation [191].
The eﬀectiveness of a dietary portfolio consisting of soy
protein (25 g/day) and soluble ﬁber mix (Fibregum—100%
madeofgumacacia,whichhas90%ofsolubledietaryﬁber—
15g/day), integrated in a low SFA diet, on blood lipids and
the association between this diet and the Apo E, Apo A1,and
ABCG5/8 polymorphisms were investigated in hyperlipi-
demicindividuals[192].Signiﬁcantdecreasesinplasmatotal
cholesterol and TG concentrations was observed; 51% of the
individuals had >20% reduction in plasma total cholesterol
concentration, and 77% had a reduction >20% in plasma
TG concentration.Among hypercholesterolemic individuals,
14% had the ABCG8 (+52G/C)polymorphism, 65% had the
ABCG5 (+1950 C/G and G/G) polymorphism, 53.5% the
Apo A1 (−75G/A and A/A) polymorphism, and 23.3% had
the Apo E (ε4) polymorphism. The presence of ABCG5/8
has been associated with reduction of absorption of plant
sterols and cholesterol from the diet by eﬄuxing these
sterols from the enterocyte back into the intestinal lumen
and by facilitating eﬃcient secretion of plant sterols and
cholesterol from hepatocytes into the bile [193]. However,
independently of genotype, the combination of cholesterol-
lowering foods in a low-saturated fat diet improved lipid
proﬁle. Another interesting study examined the eﬀect of the
dietary fat saturation when −75G/A mutation was present.
Fifty men and women were ﬁrst fed with a saturated fat
diet (17% SFA) for 28 days, followed by a MUFA diet (22%
MUFA)for35daysandaPUFAdiet(13%PUFA)for35days.
The allele frequency for the A allele was 0.13 and individuals
who carry this allele had higher cholesterol, LDL, and TG
levels than those with G/G. In women with the A allele, the
PUFA diet was compared to the saturated-fat-diet-induced
signiﬁcant decreases in total and LDL concentrations. These
resultssuggestedthattheG/Apolymorphismappears tohave
as m a l lb u ts i g n i ﬁ c a n te ﬀect on plasma LDL responsiveness
to changesin dietary fat saturation specially in women [109].
Selected studies on the main interactions of Apo poly-
morphisms with dietary factors are in Table 2.
7.ApolipoproteinA2
Synthesized in the liver, apolipoprotein A2 (Apo A2) is the
second most abundant protein of HDL particles and can be
found with the Apo A1 in subfractions of HDL. However,
its function remains largely unknown [111]. Although some
initial studies reported an inverse relationship between
plasma Apo A2 concentration and cardiovascular risk [194,
195],ﬁndings ofsubsequentstudiesdidnotrevealsigniﬁcant
associations orevensuggest aproatherogenicrole[196–198].
Several SNPs have been reported in Apo A2 gene, but
only MSP-I and −265T/C have been associated with plasma
lipid concentration [113]. MSP-1 was analyzed in a study of
1,102 individuals from the Paciﬁc island of Kosrae, in which
several other candidate genes for increased cardiovascular
risk were also tested. The carriers of the less frequent MSP-1
allele had higher serum TG concentration and, interestingly,
reduced blood pressure [199].
The most studied SNP in the literature is the −265
T/C (rs5082) that may aﬀect element D of the Apo A214 Journal of Obesity
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i
n
t
e
r
a
c
t
i
o
n
s
w
e
r
e
n
o
t
s
i
g
n
i
ﬁ
c
a
n
t
i
n
m
e
n
5
0
s
u
b
j
e
c
t
s
v
o
l
u
n
t
a
r
i
e
s
m
e
m
b
e
r
s
o
f
t
w
o
u
r
b
a
n
r
e
l
i
g
i
o
u
s
c
o
m
m
u
n
i
t
i
e
s
w
i
t
h
4
7
,
1
m
e
d
i
u
m
a
g
e
[
1
0
9
]
G
a
l
l
e
l
e
:
8
7
%
A
a
l
l
e
l
e
:
1
3
%
C
l
i
n
i
c
a
l
T
r
i
a
l
S
u
b
j
e
c
t
s
w
e
r
e
ﬁ
r
s
t
f
e
d
a
S
F
A
d
i
e
t
f
o
r
2
8
d
a
y
s
,
f
o
l
l
o
w
e
d
b
y
a
M
U
F
A
d
i
e
t
f
o
r
3
5
d
a
y
s
a
n
d
a
P
U
F
A
d
i
e
t
f
o
r
3
5
d
a
y
s
.
T
h
e
A
a
l
l
e
l
e
c
a
r
r
i
e
r
s
h
a
d
h
i
g
h
e
r
p
l
a
s
m
a
C
T
,
L
D
L
-
c
,
a
n
d
T
G
l
e
v
e
l
s
t
h
a
n
t
h
e
G
h
o
m
o
z
y
g
o
u
s
a
l
l
e
l
e
(
P
<
.
0
5
)
.
P
U
F
A
d
i
e
t
-
i
n
d
u
c
e
d
s
i
g
n
i
ﬁ
c
a
n
t
l
y
g
r
e
a
t
e
r
C
T
(
P
=
,
0
0
3
)
a
n
d
L
D
L
-
c
d
e
c
r
e
a
s
e
s
(
P
=
,
0
0
1
)
i
n
G
/
A
w
o
m
e
n
t
h
a
n
i
n
G
/
G
a
s
c
o
m
p
a
r
e
d
t
o
S
F
A
d
i
e
t
.
T
h
e
v
a
r
i
a
b
i
l
i
t
y
i
n
L
D
L
-
c
r
e
s
p
o
n
s
e
f
r
o
m
t
h
e
S
F
A
d
i
e
t
t
o
t
h
e
P
U
F
A
d
i
e
t
i
n
w
o
m
e
n
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
L
D
L
-
c
(
5
5
,
1
%
)
,
w
a
i
s
t
h
i
p
r
a
t
i
o
(
1
1
,
4
%
)
,
a
n
d
t
h
e
G
/
A
p
o
l
y
m
o
r
p
h
i
s
m
(
1
0
%
)
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T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
G
e
n
e
V
a
r
i
a
n
t
P
o
p
u
l
a
t
i
o
n
[
r
e
f
e
r
e
n
c
e
]
F
r
e
q
u
e
n
c
y
D
e
s
i
g
n
M
a
i
n
ﬁ
n
d
i
n
g
s
3
,
0
9
3
F
r
e
n
c
h
C
a
u
c
a
s
i
a
n
s
u
b
j
e
c
t
s
w
i
t
h
T
2
D
M
[
1
1
0
]
I
n
n
o
r
m
a
l
g
l
y
c
e
m
i
a
T
:
6
3
%
,
C
:
6
2
%
I
n
T
2
D
M
s
u
b
j
e
c
t
s
T
:
3
7
%
,
C
:
3
8
%
.
C
a
s
e
-
c
o
n
t
r
o
l
s
t
u
d
y
M
a
r
g
i
n
a
l
l
y
a
s
s
o
c
i
a
t
e
d
w
i
t
h
C
T
l
e
v
e
l
s
(
P
=
.
0
2
6
)
a
n
d
w
a
i
s
t
-
t
o
-
h
i
p
r
a
t
i
o
(
P
=
.
0
2
9
)
.
N
o
t
a
s
s
o
c
i
a
t
e
d
w
i
t
h
T
2
D
M
.
A
p
o
A
2
−
2
5
6
T
/
C
(
r
s
5
0
8
2
)
3
,
4
6
2
s
u
b
j
e
c
t
s
f
r
o
m
F
r
a
m
i
n
g
h
a
m
O
ﬀ
s
p
r
i
n
g
S
t
u
d
y
(
1
,
4
5
4
W
h
i
t
e
s
)
,
T
h
e
G
O
L
D
N
S
t
u
d
y
(
1
,
0
7
8
W
h
i
t
e
s
)
a
n
d
B
P
R
S
t
u
d
y
(
9
3
0
H
i
s
p
a
n
i
c
s
o
f
C
a
r
i
b
b
e
a
n
o
r
i
g
i
n
)
[
1
1
1
]
C
C
s
u
b
j
e
c
t
s
b
e
t
w
e
e
n
F
r
a
m
i
n
g
h
a
m
a
n
d
G
O
L
D
N
:
1
5
%
;
i
n
B
P
R
s
t
u
d
y
:
1
0
,
5
%
.
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
,
f
o
l
l
o
w
-
u
p
(
2
0
y
e
a
r
s
)
,
a
n
d
c
a
s
e
-
c
o
n
t
r
o
l
a
n
a
l
y
s
e
s
.
N
o
s
i
g
n
i
ﬁ
c
a
n
t
a
s
s
o
c
i
a
t
i
o
n
w
i
t
h
H
D
L
-
c
.
W
h
e
n
S
F
A
i
n
t
a
k
e
i
s
l
o
w
(
≤
2
2
g
/
d
)
,
t
h
e
S
N
P
d
o
e
s
n
o
t
a
ﬀ
e
c
t
B
M
I
.
W
h
e
n
S
F
A
i
n
t
a
k
e
i
s
h
i
g
h
(
≥
2
2
g
/
d
)
,
S
N
P
i
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
B
M
I
a
n
d
o
b
e
s
i
t
y
:
a
m
e
a
n
i
n
c
r
e
a
s
e
o
f
6
.
2
%
B
M
I
(
P
<
.
0
5
)
.
C
C
g
e
n
o
t
y
p
e
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
h
i
g
h
e
r
o
b
e
s
i
t
y
p
r
e
v
a
l
e
n
c
e
i
n
a
l
l
p
o
p
u
l
a
t
i
o
n
s
o
n
l
y
i
n
t
h
e
h
i
g
h
-
S
F
A
i
n
t
a
k
e
s
t
r
a
t
u
m
.
4
,
6
0
2
s
u
b
j
e
c
t
s
f
r
o
m
t
w
o
i
n
d
e
p
e
n
d
e
n
t
p
o
p
u
l
a
t
i
o
n
s
:
–
h
i
g
h
–
c
a
r
d
i
o
v
a
s
c
u
l
a
r
r
i
s
k
M
e
d
i
t
e
r
r
a
n
e
a
n
–
m
u
l
t
i
e
t
h
n
i
c
A
s
i
a
n
p
o
p
u
l
a
t
i
o
n
i
n
c
l
u
d
i
n
g
C
h
i
n
e
s
e
,
M
a
l
a
y
s
a
n
d
A
s
i
a
n
I
n
d
i
a
n
s
)
[
1
1
2
]
F
r
e
q
u
e
n
c
y
o
f
C
C
s
u
b
j
e
c
t
s
d
i
ﬀ
e
r
e
d
s
t
r
o
n
g
l
y
a
m
o
n
g
C
h
i
n
e
s
e
,
M
a
l
a
y
s
a
n
d
A
s
i
a
n
I
n
d
i
a
n
s
(
1
–
1
5
%
)
.
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
s
t
u
d
y
:
a
n
a
l
y
z
e
d
g
e
n
e
-
d
i
e
t
i
n
t
e
r
a
c
t
i
o
n
s
b
e
t
w
e
e
n
t
h
e
A
P
O
A
2
−
2
6
5
T
>
C
a
n
d
S
F
A
i
n
t
a
k
e
o
n
B
M
I
a
n
d
o
b
e
s
i
t
y
.
I
n
M
e
d
i
t
e
r
r
a
n
e
a
n
i
n
d
i
v
i
d
u
a
l
s
,
t
h
e
C
C
g
e
n
o
t
y
p
e
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
a
6
.
8
%
g
r
e
a
t
e
r
B
M
I
i
n
t
h
o
s
e
c
o
n
s
u
m
i
n
g
a
h
i
g
h
-
S
F
A
d
i
e
t
(
≥
2
2
g
/
d
)
,
(
P
=
.
0
1
8
)
,
b
u
t
n
o
t
a
l
o
w
(
≤
2
2
g
/
d
)
,
(
P
=
.
3
1
6
)
S
F
A
d
i
e
t
.
C
C
g
e
n
o
t
y
p
e
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
h
i
g
h
e
r
o
b
e
s
i
t
y
p
r
e
v
a
l
e
n
c
e
i
n
C
h
i
n
e
s
e
a
n
d
A
s
i
a
n
I
n
d
i
a
n
s
o
n
l
y
w
i
t
h
a
h
i
g
h
-
S
F
A
i
n
t
a
k
e
(
P
=
.
0
3
6
)
.
8
8
n
o
r
m
o
l
i
p
i
d
e
m
i
c
y
o
u
n
g
m
e
n
f
r
o
m
S
p
a
i
n
[
1
1
3
]
C
T
+
C
C
:
6
0
%
T
T
:
4
0
%
C
l
i
n
i
c
a
l
t
r
i
a
l
:
s
u
b
j
e
c
t
s
w
e
r
e
g
i
v
e
n
a
f
a
t
t
y
m
e
a
l
c
o
n
t
a
i
n
i
n
g
1
g
f
a
t
a
n
d
7
m
g
c
h
o
l
e
s
t
e
r
o
l
/
k
g
w
e
i
g
h
t
a
n
d
c
a
p
s
u
l
e
s
c
o
n
t
a
i
n
i
n
g
6
0
,
0
0
0
I
U
v
i
t
a
m
i
n
A
.
P
o
s
t
p
r
a
n
d
i
a
l
l
i
p
e
m
i
a
w
a
s
a
s
s
e
s
s
e
d
d
u
r
i
n
g
t
h
e
1
1
h
f
o
l
l
o
w
i
n
g
t
h
e
m
e
a
l
.
C
a
r
r
i
e
r
s
o
f
t
h
e
C
a
l
l
e
l
e
h
a
v
e
s
i
g
n
i
ﬁ
c
a
n
t
l
y
l
o
w
e
r
p
o
s
t
p
r
a
n
d
i
a
l
i
n
c
r
e
a
s
e
s
i
n
p
l
a
s
m
a
t
o
t
a
l
T
G
a
n
d
c
h
y
l
o
m
i
c
r
o
n
T
G
,
s
u
g
g
e
s
t
i
n
g
a
p
r
o
t
e
c
t
i
v
e
e
ﬀ
e
c
t
a
g
a
i
n
s
t
c
a
r
d
i
o
v
a
s
c
u
l
a
r
d
i
s
e
a
s
e
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T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
G
e
n
e
V
a
r
i
a
n
t
P
o
p
u
l
a
t
i
o
n
[
r
e
f
e
r
e
n
c
e
]
F
r
e
q
u
e
n
c
y
D
e
s
i
g
n
M
a
i
n
ﬁ
n
d
i
n
g
s
2
,
1
4
8
s
u
b
j
e
c
t
s
f
r
o
m
t
h
e
F
r
a
m
i
n
g
h
a
m
O
ﬀ
s
p
r
i
n
g
S
t
u
d
y
w
i
t
h
5
0
,
4
5
m
e
d
i
u
m
a
g
e
[
1
1
4
]
T
a
l
l
e
l
e
:
8
6
,
6
%
C
a
l
l
e
l
e
:
1
3
,
4
%
C
a
l
l
e
l
e
:
8
8
,
3
%
G
a
l
l
e
l
e
:
1
1
,
7
%
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
S
i
g
n
i
ﬁ
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
s
b
e
t
w
e
e
n
t
h
e
−
1
1
3
1
T
/
C
a
n
d
P
U
F
A
i
n
t
a
k
e
w
a
s
f
o
u
n
d
(
P
=
.
0
0
1
)
i
n
d
e
t
e
r
m
i
n
i
n
g
f
a
s
t
i
n
g
p
l
a
s
m
a
T
G
,
R
L
P
,
a
n
d
p
a
r
t
i
c
l
e
s
i
z
e
.
T
h
e
s
a
m
e
r
e
s
u
l
t
s
c
o
u
l
d
n
o
t
b
e
o
b
s
e
r
v
e
d
i
n
5
6
C
/
G
p
o
l
y
m
o
r
p
h
i
s
m
.
I
n
i
n
d
i
v
i
d
u
a
l
s
w
h
o
c
o
n
s
u
m
e
d
a
h
i
g
h
P
U
F
A
d
i
e
t
(
6
%
o
f
t
h
e
e
n
e
r
g
y
)
,
t
h
e
−
1
1
3
1
T
/
C
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
h
i
g
h
e
r
f
a
s
t
i
n
g
T
G
a
n
d
R
L
P
c
o
n
c
e
n
t
r
a
t
i
o
n
(
P
=
.
0
1
)
.
T
h
e
s
i
z
e
o
f
V
L
D
L
i
n
c
r
e
a
s
e
s
a
n
d
L
D
L
d
e
c
r
e
a
s
e
s
w
h
i
l
e
P
U
F
A
i
n
t
a
k
e
i
n
c
r
e
a
s
e
d
i
n
t
h
e
−
1
1
3
1
T
/
C
c
a
r
r
i
e
r
s
.
T
h
e
P
U
F
A
A
p
o
A
5
i
n
t
e
r
a
c
t
i
o
n
s
w
e
r
e
s
p
e
c
i
ﬁ
c
f
o
r
d
i
e
t
a
r
y
n
-
6
f
a
t
t
y
a
c
i
d
s
.
A
p
o
A
5
−
1
1
3
1
T
/
C
(
r
s
6
6
2
7
9
9
)
5
6
C
/
G
(
r
s
3
1
3
5
5
0
6
)
2
,
2
8
0
s
u
b
j
e
c
t
s
f
r
o
m
t
h
e
F
r
a
m
i
n
g
h
a
m
O
ﬀ
s
p
r
i
n
g
S
t
u
d
y
w
i
t
h
5
4
,
2
m
e
d
i
u
m
a
g
e
[
1
1
5
]
T
a
l
l
e
l
e
:
8
7
,
1
5
%
C
a
l
l
e
l
e
:
1
2
,
8
5
%
C
a
l
l
e
l
e
:
8
8
,
9
5
%
G
a
l
l
e
l
e
:
1
1
,
0
5
%
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
A
s
i
g
n
i
ﬁ
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
b
e
t
w
e
e
n
−
1
1
3
1
T
/
C
a
n
d
t
o
t
a
l
f
a
t
i
n
r
e
l
a
t
i
o
n
t
o
t
h
e
B
M
I
(
P
=
,
0
0
1
)
w
a
s
f
o
u
n
d
.
T
h
e
−
1
1
3
1
C
m
i
n
o
r
a
l
l
e
l
e
c
a
r
r
i
e
r
s
h
a
d
a
l
o
w
e
r
o
b
e
s
i
t
y
(
P
=
.
0
3
2
)
a
n
d
o
v
e
r
w
e
i
g
h
t
(
P
=
.
0
3
1
)
r
i
s
k
w
h
e
n
c
o
m
p
a
r
e
d
w
i
t
h
T
T
s
u
b
j
e
c
t
s
i
n
t
h
e
h
i
g
h
f
a
t
i
n
t
a
k
e
g
r
o
u
p
,
b
u
t
n
o
t
w
h
e
n
f
a
t
i
n
t
a
k
e
w
a
s
l
o
w
(
P
=
.
4
8
)
.
T
h
e
m
o
n
o
u
n
s
a
t
u
r
a
t
e
d
f
a
t
t
y
a
c
i
d
s
i
n
t
a
k
e
s
h
o
w
e
d
t
h
e
h
i
g
h
e
s
t
s
t
a
t
i
s
t
i
c
a
l
s
i
g
n
i
ﬁ
c
a
n
c
e
f
o
r
t
h
e
s
e
i
n
t
e
r
a
c
t
i
o
n
s
.
1
,
0
2
0
o
f
t
h
e
B
o
s
t
o
n
P
u
e
r
t
o
R
i
c
a
n
H
e
a
l
t
h
S
t
u
d
y
a
t
a
g
e
4
5
–
7
5
[
1
1
5
]
T
h
e
p
a
i
r
w
i
s
e
L
D
c
o
e
ﬃ
c
i
e
n
t
R
b
e
t
w
e
e
n
t
h
e
A
P
O
A
5
−
1
1
3
1
T
/
C
a
n
d
5
6
C
/
G
w
a
s
0
,
0
1
6
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
T
h
e
5
6
C
/
G
p
o
l
y
m
o
r
p
h
i
s
m
w
a
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
H
D
L
-
c
(
P
=
.
0
4
4
)
.
T
h
e
m
i
n
o
r
a
l
l
e
l
e
c
a
r
r
i
e
r
s
h
a
d
l
o
w
e
r
H
D
L
-
c
t
h
a
n
t
h
o
s
e
w
i
t
h
c
o
m
m
o
n
v
a
r
i
a
n
t
(
P
=
.
0
1
2
)
.
B
o
t
h
p
o
l
y
m
o
r
p
h
i
s
m
s
w
e
r
e
a
s
s
o
c
i
a
t
e
d
w
i
t
h
T
G
o
r
o
t
h
e
r
l
i
p
i
d
s
.
A
s
s
o
c
i
a
t
i
o
n
s
o
f
t
h
e
−
1
1
3
1
T
/
C
w
i
t
h
t
o
t
a
l
f
a
t
e
n
e
r
g
y
i
n
t
a
k
e
w
a
s
o
b
s
e
r
v
e
d
f
o
r
T
G
(
P
=
.
0
3
2
)
a
n
d
C
T
(
P
=
.
0
3
4
)
.
−
1
1
3
1
T
/
C
(
r
s
6
6
2
7
9
9
)
4
9
m
a
l
e
s
u
b
j
e
c
t
s
a
t
a
g
e
2
8
–
5
5
y
e
a
r
s
w
e
r
e
r
e
c
r
u
i
t
e
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promoter,reportedtobefunctionalin2independentstudies,
in which C allele was associated with decreased plasma Apo
A2 concentration [200, 201]. In agreement, a meta-analysis
of data from 12,387 subjects found no association of this
SNP with T2DM [110]. The C allele was associated with
waist circumference in men [200] and in white woman, but
not in African-American woman [202]. In addition, plasma
Apo A2 concentration was signiﬁcantly lower in carriers of
C allele, while postprandial Apo B100 in the large VLDL
particles (Sf > 60) were lower only in those in homozygous
for the C allele (P = .01) [200]. Discordantly, in other study
carriers of the C allele had signiﬁcantly lower postprandial
increases in plasma total and chylomicron TG, suggesting
a protective cardiovascular eﬀect, which may be related
to the lowered risk of postprandial hypertriglyceridemia
[113].
A gene-diet interaction inﬂuencing BMI and obesity has
been strongly and consistently replicated in many studies.
Interactions between the −265T/C and SFA intake on
BMI and obesity in 3,462 individuals from three American
populations: Framingham Oﬀspring Study: (FOS) (1,454
Whites), Genetics of Lipid Lowering Drugs and Diet Net-
work: (GOLDN) Study (1,078 Whites), and Boston-Puerto
Rican: (BPR) Study (930 Hispanics of Caribbean origin).
Frequencies of CC individuals did not diﬀer between FOS
and GOLDN (15% in both), but this was lower in the
BPR Study (10.5%). No signiﬁcant association of the SNP
with plasma HDL-c concentration was found among all the
three populations. Also, statistically signiﬁcant interactions
between this SNP and SFA intake were detected: when SFA
intake is low (≤22g/d), the −265T>C SNP did not aﬀect
BMI. However, when SFA intake was high (≥22g/d), this
SNP is strongly associated with BMI and obesity: a mean
increase of 6.2% BMI (4.3%–7.9%; P<. 05). Moreover,
the CC genotype was signiﬁcantly associated with higher
obesity prevalence in all populations only in the high-SFA
intake stratum [111]. Similar results were showed in a cross-
sectional study with 4,602 subjects from two independent
populations (a high-cardiovascular risk Mediterranean and
a multiethnic Asian population including Chinese, Malays,
and Asian Indians). In this study, the frequency of CC
subjects diﬀered strongly among populations (1–15%) and
an interaction of Apo A2 with saturated fat on body
weight was conﬁrmed: in Mediterranean subjects, the CC
genotype was associated with a 6.8% greater BMI in those
consuming a high (P = .018), but not a low (P =
.316) SFA diet. Likewise, the CC genotype was signiﬁcantly
associated with higher obesity prevalence in Chinese and
Asian Indians, only those with a high SFA intake (P = .036)
[112].
Despite the evidences of the inﬂuence of the ApoA2
−265T/C polymorphism on body-weight-related measures,
modulated by saturated fat consumption, in diﬀerent pop-
ulations, its role in the control of circulating lipoproteins
and cardiovascular risk proﬁle is not completely under-
stood.
Selected studies on the main interactions of Apo poly-
morphisms with dietary factors are in Table 2.
8.ApolipoproteinA5
It was well known that the main genetic factor related
to the plasma triglyceride determination is apolipoprotein
C3, however trying to better understand the mechanisms,
an intensive investigation of DNA sequence around the
APOA1/APOC3/APOA4 gene cluster was conducted [203].
Therefore the available mice and human sequences (about
200000bp) around this locus were completed by sequencing
and compared, leading to the identiﬁcation of evolutionary
highly conserved sequence that contained a putative lipid-
binding apolipoprotein gene, named the Apo A5 [204, 205].
The human Apo A5 gene consists of 4 exons and codes 369
aminoacid protein, which is expressed almost exclusively in
theliver[204].ApoA5islocatedontriglyceriderichparticles
(chylomicrons and very low density lipoproteins—VLDL)
and HDL particles. An inverse relationship between APO
A5 and TG levels has been described in animal studies, in
which knockout mice developed hypertriglyceridemia and
transgenic mice overexpressing APO A5 reduces plasma TG
levels [204].
In comparison to other apolipoproteins, the plasma
concentration of Apo A5 is low in human—about 100μg/L
[206]. In addition, researches conﬁrm that Apo A5 binds
to and enhances the activity of lipoprotein lipase (LPL)
enzyme and, consequently, reduces triglyceride levels in
VLDL particles. Moreover, the treatment in mice with Apo
A5 lead to a reduction of VLDL-triglyceride production rate,
but the concentration of the VLDL particles was the same as
in normal mice [206, 207]. These results conﬁrmed that Apo
A5 plays a role in the LPL activation.
To identify common polymorphisms, extensive sequenc-
ing of the Apo A5 interval in humans has been performed.
A set of 4 common polymorphisms (SNPs1 through 4; also
named 259T/C,IVS3+476G/A, −1131T/C,and −12,238T/C,
resp.) were ﬁrst identiﬁed within the human Apo A5.
Statistical analysis indicated that the minor alleles SNPs 1
through 3 formed a relatively common haplotype that is
found in approximately 15% of Whites [204, 208].
Subsequently, through direct DNA sequencing of the
gene in 116 hyperlipidemic individuals, 9 additional SNPs
were identiﬁed. One of the polymorphisms (−3A/G) was
found to be in strong linkage disequilibrium with the minor
alleles for SNPs 1 trough 3 and this haplotype was named
APOA5∗2. In addition, a second common polymorphism
wasalsoidentiﬁed,which resultsinaCtoGnonsynonymous
substitution (56C/G) that changes codon 19 from serine to
tryptophan. Further haplotype analysis in Whites indicated
that the minor allele of this polymorphism deﬁnes a third
common Apo A5 haplotype (APOA5 ∗3), and this one was
also found in almost 15% of Whites. The remaining 7 poly-
morphisms from this study were either uncommon or not
obviously associated with plasma triglycerides concentration
[208].
Thus, polymorphism discovery andhaplotype analysisin
Whites deﬁned 3 common haplotypes in the Apo A5 interval
and provided detailed information for genetic association
studies in humans. In these analyses, the −1131T/C allele
(SNP3-rs662799) was used as a marker to deﬁne APOA5 ∗2,Journal of Obesity 19
whereas the 56C/G allele (S19W-rs3135506) was used to
deﬁne APOA5 ∗3 [208].
Carriers of the less frequent allele −1131T/C have higher
concentrations of plasma triglycerides, both in fasting [209]
and postprandial [210] states, and total cholesterol, lower
blood HDL-c [211], smaller LDL particles [212], and are at
higher cardiovascular risk [213]. Moreover, carriers of allele
56C/G show an increase in triglyceride levels, independently
of the eﬀects observed for the −1131T/C, as well as an
increased risk of suﬀering from atherosclerosis [214].
In this context, it is most commonly found in the
literature studies that related −1131T/C and 56C/G SNPs
to dietary factors. Thus, Lai et al. [114]h a v ep r o p o s e dt o
investigate the interaction between Apo A5 gene variation
and dietary fat in determining plasma fasting triglycerides,
remnant-like particle (RLP) concentrations, and lipopro-
tein particle size in 1001 men and 1147 women who
were Framingham Heart Study participants. They found
a signiﬁcant gene-diet interactions between the −1131T/C
polymorphism and PUFA intake in determining fasting
triglyceride, RLP concentrations, and particle size. However,
these interactions were not observed for the 56C/G poly-
morphism. The −1131C allele was associated with higher
fasting triglyceride and RLP concentrations (P<. 01) only
in the individuals consuming a high-PUFA diet (>6% of
total energy). Similar interactions were found for the sizes
of VLDL and LDL particles. Only in carriers of the −1131C
allele did the size of these particles increase (VLDL) or
decrease (LDL) as PUFA intake increased (P<. 01). The
authors further analyzed the eﬀects of w-6 and w-3 fatty
acids, and found that the interactions between PUFA and
Apo A5 were speciﬁc for dietary n-6 fatty acids.
Anotherresearch involving theFramingham Heart Study
participants concluded that Apo A5 gene variation modu-
lates the eﬀects of dietary fat intake on BMI and obesity
risk. The authors investigated the interaction between the
Apo A5 −1131T/C and 56C/G polymorphisms and the
macronutrient intake (total fat, CHO, and protein) in their
relation tothe BMIand obesity risk. They found asigniﬁcant
interaction between the −1131T/C SNP and total fat intake
for BMI. In individuals homozygous for the −1131T major
allele, BMIincreased as totalfat intakeincreased. In contrast,
thisincrease wasnotpresentincarriersofthe −1131Cminor
allele. Signiﬁcant interactions were found in determining
obesity and overweight risks, since the Apo A5 −1131C
minor allele carriers had a lower obesity risk (OR 0.61, P =
.032) and overweight risk (OR 0.63, P = .031) compared
to TT individuals in the high-fat intake group (≥30% of
energy) but not when fat intake was low (OR 1.16, P =
.47 and OR 1.15, P = .48) for obesity and overweight,
respectively. When speciﬁc fatty acid groups were analyzed,
MUFA showed the highest statistical signiﬁcance for these
interactions [215].
A more recent study [115] that aimed to determine the
association of the same Apo A5 polymorphism previously
mentioned with plasma lipids and markers of MS, alone and
in interaction with total fat intake in Puerto Ricans (n =
802, 45–75 yrs) found interesting results. Apo A5 S19W was
associated with HDL (P<. 05). Neither polymorphism was
associated with triglyceride or other lipids, butinteraction of
the −1131T/C SNP with total fat energy intake was observed
for plasma triglyceride (P = .032) and total cholesterol
(P = .034). Apo A5 56C/G interacted with total fat intake
in association with systolic and diastolic blood pressure (P<
.001).
As previously cited, Apo A5 mutations have been exten-
sively related to the postprandial lipemic response. Kim et al.
[116] compared low-fat (LF) meal and high-fat (HF) meal
on the postprandial lipemic responses according to the
−1131T/C polymorphism of the APOA5 gene. Fasting total
triglycerideswerehigherinheterozygousfortheCallele(TC)
and homozygous for C allele (CC) men than homozygous
for the T allele (TT) men, but fasting chylomicron TG were
not signiﬁcantly diﬀerent between TT men and C carriers.
TT individuals had no signiﬁcant diﬀerences in postprandial
responses of total TG and chylomicron TG and postprandial
mean changes of chylomicron TG between LF and HF meal.
On the other hand, C carriers had delayed peak time of total
TG compared to TT individuals and higher postprandial
response and mean changes of chylomicron TG at HF meal
compared to LF meal. The authors hypothesized that these
facts occur due to the limiting capacity to clear chylomicron
TG or hydrolyze TG on HF diet in TC and CC men, resulting
in higher postprandial triglyceridemia.
Vitamin E also has been related to Apo A5 polymorph-
isms since it is a lipophilic micronutrient that is also
transported within lipoproteins. The eﬀects of the Apo A5
−1131T/C gene variant according to vitamin E status (α-
tocopherol, γ-tocopherol, buccal mucosa cells total vitamin
E, LDL α-tocopherol, and LDL γ-tocopherol) and lipid
proﬁle(VLDL,HDL,intermediatedensitylipoprotein(IDL),
and LDL) were investigated. C allele carriers showed signif-
icantly higher TG, VLDL, and LDL concentrations, higher
cholesterol in VLDL and IDL, and higher plasma fatty
acids. Plasma α-tocopherol was increased signiﬁcantly in C
allele carriers compared with homozygote T allele carriers
(P = .02), suggesting that higher plasma lipids in the TC
and CC genotypes were eﬃciently protected against lipid
peroxidation by higher plasma α-tocopherol concentration
[117].
Selected studies on the main interactions of Apo poly-
morphisms with dietary factors in Table 2.
9.ApolipoproteinE
ApoEwasdiscoveredin1970asa componentoftriglyceride-
rich lipoproteins [216]. It is an amphipathic 299 amino
acid glycoprotein of 34,145KDa that is mainly secreted by
hepatocytes [217], but expressed in the brain and liver [218].
The primary functional role of Apo E is to transport and
deliver lipids mainly through the LDL-c receptor pathway.
A secondary proposed pathway involves the heparin sul-
phate proteoglycan (HSPG)/LDL-C receptor-related protein
pathway [219]. Apo E acting as a ligand for these receptors
[220] plays a crucial role in determining the metabolic fate
of plasma lipoproteins and consequently of cholesterol [220,
221], while its accumulation on the surface of lipoproteins20 Journal of Obesity
can decrease the lipolysis rate of TG by lipase [222–224].
Furthermore, Apo E as a component of HDL inﬂuences the
cholesterol inﬂux and eﬄux of cells [225–227].
Plasma Apo E isoforms have two kinds of polymor-
phism, one genetically determined and one not. The former
polymorphism is the result of three alleles, called epsilon
(ε) alleles: ε2, ε3, and ε4 at a single gene locus and that
diﬀers in 112 e 158 position of the aminoacids (Apo E2:
Cys112-Cys158; Apo E3: Cys112-Arg158; Apo E4: Arg112-
Arg158). The relative frequency in white population of
Apo E2, Apo E3, and Apo E4 alleles is 0,08, 0,77, and
0,15, respectively [228]. This alleles can form six genotypes
ranking in order of most to least common (ε33, ε34, ε23,
ε44, ε24, and ε22) [229]. The ε33 genotype, being the most
common, is used as reference for all Apo-E-related func-
tions [230]. The nongenetically determined polymorphism
results from variable posttranslational sialyation of Apo E
and accounts for 10%–20% of plasma Apo E [219]. In
addition, Apo E isoforms are important determinants of
postprandial lipemia [231]. It has been demonstrated that
Apo E2 homozygous subjects have the lowest aﬃnity for
TRL remnant receptors, and this genotype is associated
withdelayed postprandial clearance.A recent Brazilianstudy
indicates that carriers of Apo E4 had a positive association
with higher total cholesterol (P<. 001), LDL-C (P<
.001), total-cholesterol/HDL-C ratio (P<. 001), LDL/HDL-
Cr a t i o( P<. 001), lower HDL-C values (P<. 001),
and higher risk to obesity (OR = 1.358, 95% CI = 1.019–
1.811)[232].Furthermore,patientswithMS,withgenotypes
other than the Apo E3/3, are at greater risk of postprandial
hypertriglyceridemia and hyperuricemia following the acute
ingestion of a fat overload [233]. Several studies have shown
interaction between the postprandial lipemic response and
Apo E polymorphisms. Subjects who are carriers of the
−219T allele, which is located in the promoter region of
the Apo E gene, −219G/T, display lower levels of Apo E in
plasma in both fasting and postprandial states, and thiseﬀect
was associated with a stronger postprandial response, and a
decrease in transcription activity [231].
Moreno et al. [119] evaluated whether the quantity and
quality of dietary fat interacts with the Apo E genotype and
sex modifying plasma Apo E levelsin young healthy subjects.
Theparticipantswer esubjectedtothr eedietaryperiods,each
o n eo f4w e e k s .T h eﬁ r s tw a saS F A - e n r i c h e dd i e t( 3 8 %f a t ,
being 20% SFA, 12% MUFA, and 6% PUFA), which was
followed by a CHO rich diet (55% CHO, <30% fat, being
10% SFA, 12% MUFA, and 6% PUFA) or a MUFA-rich diet
(38% fat, being <10% SFA, 22% MUFA and 6% PUFA).Apo
E2 carriers have the highest Apo E levels, whereas Apo E4
individuals show the lowest concentration after the saturated
fat, CHO, and MUFA diets. Women had signiﬁcantly higher
ApoEconcentrationthanmenonlyaftertheconsumptionof
the high-saturated fat diet. The SFA-enriched diet increased
the Apo E plasma concentration when compared with the
CHO-, and MUFA-rich diets in women, but not in men.
In women, but not in men, the shift from the SFA- to
CHO- or MUFA-rich diets signiﬁcantly decreased the Apo
E concentration in apoE3/2 and apoE3/3 subjects, whereas
no diﬀerences were observed in women with the apoE4/3
genotype. They concluded that sex and Apo E genotype
determine Apo E circulating levels; however, this eﬀect is
dependent on dietary fat.
Loktionov et al. [120] investigated the relationship
between Apo E genotype and the eﬀects of a CHD-promot-
ing diet in free-living individuals. No relationship between
dietary fats and cholesterol levels were observed in the
E2 or E3 group when analyzed separately. However, the
presence of the E4 allele resulted in positive associations
between total and saturated fat intake with total cholesterol
and LDL. When expressing fat and saturated fat intake as
a percentage of total energy intake compared to absolute
amounts, this relationship was stronger. The study suggested
that individuals with the E4 allele may be more responsive
to the dietary therapy. Calculations showed that cutting
saturated fat consumption in half resulted in a 20% decrease
in LDL in those with the E4 allele compared to just a 5%
decrease in those without. This speculation is supported by
the results of Dreon et al. [234] who found that that LDL-
lowering eﬀectsofa low-fat diet were greaterinmen with the
E4 allele than those without.
A prospective transversal cohort study including 22,915
participants of the Norfolk arm of the European Prospective
Investigation of Cancer (EPIC Norfolk) investigated whether
bloodlipidresponse todietaryfatandﬁbersvariedaccording
to the Apo E gene locus. Signiﬁcant (P<. 001) diﬀerences
in serum lipids according to genotype were found. Highest
total and LDL and lowest HDL and TG levels were detected
inε4/ε4individuals.TotaldietaryfatandSFAwereassociated
withtotalandLDLcholesterolconcentrationsandsigniﬁcant
inverse associations between PUFA and dietary ﬁber and
lipid fractions were found. Associations were in the same
direction for ε2, ε3, and ε4 expressing individuals with no
signiﬁcant interactions between diet and genotype group on
blood lipids, except in the 3% individuals expressing ε2/ε4
(P<. 05) in whom the associations were doubled [118].
Strandhagen et al. [121] hypothesized that the increase
of plasma CT and TG stimulated by the ingestion of the
coﬀee might be modulated by the Apo ε2/ε3/ε4. The subjects
were submitted to four periods of intervention: two of
them included three free weeks of coﬀee and the others
two included the ingestion of 600mL/day for four weeks.
The cholesterol-raising eﬀect of coﬀee was not inﬂuenced
signiﬁcantly by the Apo E allele carriers status, however
individuals with Apo ε2 polymorphism had signiﬁcantly
lower total cholesterol concentration at baseline (P = .01).
Selected studies on the main interactions of Apo poly-
morphisms with dietary factors are in Table 2.
10.GlutathionePeroxidases
GPx1 and GPx2 have antioxidant functions, protecting cells
from oxidative stress damage. Knockout mice lacking both
GPx1 and 2 are more susceptible to an oxidative challenge
[235]. Responses of transgenic mice lacking or overexpress-
ing GPx1 have suggested roles for GPx1 in relation to
both reactive oxygen species and reactive nitrogen species
as well as a link to insulin-mediated eﬀects [235]. GPx4Journal of Obesity 21
appears to have a complex range of functions in protection
from oxidative stress, lipoxygenase metabolism, and sperm
function [236, 237] and may play a role in regulation of
leukotriene biosynthesis which in turn regulates the biosyn-
thesis of leukotrienes, thromboxanes, and prostaglandins,
thus modulating inﬂammatory. [238].
A recent research [82] investigated the associations be-
tween glutathione peroxidase-1 Pro198Leu polymorphism,
selenium status, and DNA damage levels in obese women
after consumption of Brazil nuts. Participants consumed
one Brazil nut, which provided approximately 290 age of
Se a day, for 8 weeks. At baseline, 100% of the subjects
were Se deﬁcient, and after the supplementation, there was
an improvement in plasma Se (P<. 001 for Pro/Pro and
Pro/Leu, P<. 05 for Leu/Leu), erythrocyte Se (P = .00 for
Pro/Pro and Pro/Leu, P<. 05 for Leu/Leu), and GPx activity
(P = .00 for Pro/Pro, P<. 00001 for Pro/Leu, P<. 001 for
Leu/Leu). In addition, the Pro/Pro group showed a decrease
in DNA damage after Brazil nut consumption compared
with baseline (P<. 005), and those levels were higher in
Leu/Leu individuals compared with those with the wild-type
genotype (P<. 05).
A study about the region of the GPX4 gene corre-
sponding to the 3 UTR was scanned for mutations in a
group of 66 volunteers Scotland. The data show a T/C
variant at position 718, distribution was 34% CC, 25% TT,
and 41% TC. Individuals of diﬀerent genotypes exhibited
signiﬁcant diﬀerences in the plasma levels of 5-lipoxygenase
total products in lymphocyte, with 718C showed increased
levelsofthose productscompared to 718T and 718T/C (36%
and 44% increases, resp.). The data suggest that the SNP 718
has functional eﬀects and support the hypothesis that GPX4
plays a regulatory role in leukotriene biosynthesis [239].
The same SNP 718 (rs713041) inﬂuenced the concentra-
tion of GPx4 and other selenoproteins in vivo. A selenium
supplementationtrial was carried outwith bothhomozygote
genotypes for this SNP. Blood samples were analyzed at
baseline, after a 6 week supplementation with 100g Seleniun
(Se) as sodium selenite/day and during a 6 week washout
period. Both lymphocyte GPx1 protein concentrations and
plasma GPx3 activity increased signiﬁcantly after Se sup-
plementation in CC but not TT participants. After Se
withdrawal, there was a signiﬁcant fall in both lymphocyte
GPx4 protein concentrations and GPx4 activity in TT but
not in CC participants; this eﬀectwas modulated by sex [83].
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
11.SelenoproteinP
ThephysiologicalfunctionsofSeresultfromitsexistenceina
number ofselenoproteins in which Seis present astheamino
acidselenocysteine(Sec).Sewasﬁrst showntobeanessential
component of glutathione peroxidase and subsequently has
been found in 25 mammalian selenoproteins [240–242].
In eukaryotes Se is incorporated into selenoproteins as the
amino acid selenocysteine in a process requiring a stem loop
withinregion3 UTRofthemRNA[243].These proteinsand
their genes, as well as the factors involved in their synthesis,
provide a focus for both mechanistic and genetic studies.
Selenoproteinsynthesis and functional activity will result
from the combined inﬂuences of the genetic information
in the genes encoding the selenome and dietary Se intake.
Polymorphism in these genes could potentially inﬂuence the
Se intake required to achieve a particular level of functional
activity and thus individual requirements for Se [244].
Any functional eﬀect of a single nucleotide change is
likely to be relatively small and can be higher with a
combination of diﬀerent SNP(s) in selenoprotein-related
gene(s), possibly in combination with dietary Se intake.
When this is suboptimal, such an interaction may give rise
to diﬀerences in the ability of selenoproteins to function at
optimal capacity; thus, selenoprotein function in protection
of cells from oxidative stress or inﬂammation could be
compromised [244].
The best characterized selenoproteinsare the glutathione
peroxidases (GPxs), the thioredoxin reductases (TRs), and
deiodinases(IDIs),andselenoproteinP(SeP)[244].SePisan
extracellular glycoprotein and is expressed most abundantly
in liver and at relatively high level in kidney and heart [245].
However, the expression and regulation of SeP in adipose
tissue has not been previously reported [246, 247]. SeP
represents the best Se marker, accounting for the majority
of circulating Se in blood and responding over a broad
r a n g et oS ei n t a k e[ 248]. In addition to the role as a
selenium transporter, SeP has been postulated to possess
antioxidant properties, for instance, SeP has the ability to
bindepithelialcellsanddisplaysphospholipidhydroperoxide
thiol peroxidase activity [248]. The overexpression of SeP1
suppressed hydrogen peroxide-induced activation of JNK
and p38 in retinal pigment epithelial cells [249]. Another
study showed that the activation of GPx activity is required
for the protective role of SeP against oxidative damage in
human endothelial cells and astrocytes [250, 251] indicating
that SeP participates in the control of the cellular redox
balance. Since oxidative stress in adipose tissue has been
implicated in obesity and insulin resistance, it has been
hypothesized that antioxidant SeP may likely be involved in
cellular mechanisms of oxidative stress -linked inﬂammation
and insulin resistance [252].
A study showed that SeP1 gene expression was signiﬁ-
cantly reduced in adipose tissue of ob/ob and high-fat-diet-
induced obese mice, as well as in primary adipose cells
isolated from Zucker obese rats. Interestingly, SeP1 gene
silencing resulted in the reduction in GPX activity and the
upregulation of inﬂammatory cytokines MCP-1 and IL-6
in preadipocytes, leading to the inhibition of adipogenesis
and adipokine and lipogenic gene expression. SeP has an
important role in adipocyte diﬀerentiation via modulating
oxidative stress and inﬂammatory response [252].
A research studied two SNPs in the SeP gene, one in the
codingregion(position24731,causinganAlatoThrchange)
and one in 3 UTR (position 25191). Their frequency was
similar in Caucasian, Chinese, and South Asian populations.
Prospectively genotyped volunteers were supplemented for
6wk with 100ug sodium selenite/day. Blood samples were
analyzed for plasma Se and selenoprotein biomarkers at22 Journal of Obesity
baseline, after supplementation, and during a washout
period. Plasma Se, SeP, and GPx3 levels increased with
supplementation. Baseline plasma Se content depended on
both SeP genotypes and BMI. Presupplementation SeP
concentration was associated with gender and genotype at
SNP 24731 and postsupplementation concentration with
SNP 25191. The data revealed two common functional SNPs
within the human SePP gene that may predict behavior of
biomarkersofSestatusandresponsetosupplementationand
thus susceptibility to disease [84].
Selected studies on the main interactions of polymor-
phisms with dietary factors are in Table 1.
Several SNPs have been identiﬁed in the genes for
selenoproteins and some are linked to the occurrence of
diseases. However, the current knowledge is limited and the
further studies are needed to identify and assess the eﬀect
of these SNPs in the nutritional requirements of Se, your
metabolism, and susceptibility to diseases.
12.Conclusion
There is evidence that genetic variation at genes involved in
theetiologyofinﬂammation and dyslipidemia couldinteract
with environmental exposures, such as diet, to modulate
individuals’ susceptibility to developing these conditions.
Present data support the notion that more tailored dietary
recommendations may be helpful in the prevention of
obesity-induced comorbidities. However, the relevance and
magnitude of nutrient-gene interaction needs to be further
elucidated. It is also important to emphasize that the study
of the combined eﬀect of SNPs in diﬀerent genes, as
well as haplotypes, may be promising since gene-nutrient
interactions in obesity-induced metabolic disturbances are
complex.
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